Madrigal Pharmaceuticals struck a major licensing and acquisition push to bolster its MASH pipeline, agreeing to license six preclinical siRNA programs from China’s Ribo Life Science and paying $60 million upfront with potential milestones totaling up to $4.4 billion. The move aims to combine targeted gene silencing with Madrigal’s approved THR‑beta agonist, Rezdiffra, to create combination strategies for metabolic dysfunction‑associated steatohepatitis. Company executives framed the deals as platform expansion after Rezdiffra’s commercial success and follow several recent asset purchases including a DGAT2 inhibitor from Pfizer. The transactions emphasize a dealmaking strategy to assemble complementary mechanisms for a complex liver disease where combination regimens may prove necessary.